NovoCure (NSDQ:NVCR) today released results from the ongoing phase 2 pilot clinical trial of its Optune device combined with chemotherapy for patients with unresectable, previously untreated mesothelioma. Data from the trial is also slated to be presented at the International Association for the Study of Lung Cancer’s 17th World Conference on Lung Cancer on December 7. […]
NovoCure
Novocure reports 142% boost in sales for Q3
Shares in Novocure (NSDQ:NVCR) rose nearly 30% yesterday after the medical device maker met expectations on Wall Street with its 3rd-quarter results. The St. Helier, N.J.-based company pared its losses by -29% to -$33.6 million, or -39¢ per share, on sales of $21.7 million for the 3 months ended Sept. 30, for sales growth of 142% […]
Israeli technical institute takes a stake in NovoCure after patent settlement
A pair of Israeli technical institutes, the Technion Research and Development Foundation and the Technion – Israel Institute of Technology, agreed to accept a stake in NovoCure (NSDQ:NVCR) as part of a settlement inked last year to avert a potential patent dispute. The parties agreed in February 2015 to resolve “certain potential intellectual property disputes” between […]
Novocure enrolls 1st patient in phase III brain metastases trial
Novocure (NSDQ:NVCR) said that the 1st patient has been enrolled in a Phase III pivotal trial of its tumor-treating field technology in combination with radiosurgery to treat brain metastases from non-small-cell lung cancer. The St. Helier, N.J.-based company’s tumor treating fields (TTFields) are low-intensity, intermediate-frequency, alternating electric fields designed to disrupt cell division within cancer cells. Novocure’s commercial product, Optune, […]
Novocure touts long-term analysis of Optune drug-device combo
Novocure (NSDQ: NVCR) touted a long-term analysis of data from a Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-formed glioblastomas. Survival data for nearly 700 patients confirmed interim results from the trial, 1st published in December 2015 in the Journal of the American Medical Assn. Patients treated […]
Novocure touts data from Optune-paclitaxel combination study
By Sarah Faulkner NovoCure (NSDQ:NVCR) announced yesterday that its ‘tumor treating fields, combined with the drug paclitaxel, are effective against ovarian cancer, the 5th most-common cause of cancer death in women in the US. The St. Helier, N.J.-based company won FDA approval in July for the Optune device to treat a type of brain cancer called glioblastoma. TTFields […]
NovoCure wins FDA nod for next-gen Optune device
NovoCure (NSDQ:NVCR) said today it won FDA premarket approval for its 2nd-generation Optune system designed to treat glioblastoma patients. The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death. The next-generation device is smaller, lighter and […]
Skyline Medical CEO Kornberg steps down, Schwartz takes over as interim | Personnel Moves May 20, 2016
Skyline Medical CEO Kornberg steps down, Schwartz takes over as interim chief exec Skyline Medical said earlier this month that prez and CEO Joshua Kornberg has stepped away from his roles at the company, and is being replaced by Carl Schwartz who will serve as interim chief executive. Prior to his time at Skyline, Schwartz served […]
A new frontier in the war on brain cancer with NovoCure chairman Bill Doyle
Novocure, the St. Helier, Jersey-based medical device company, which raised more than $158M in an IPO last year, is trying to change the way we fight cancer. Company officials say its proprietary Tumor Treating Fields technology, marketed under the product name Optune, are a new tool in the war against cancer. Currently, the company has […]
FDA grants IDE to NovoCure for phase II Optune trial
NovoCure (NSDQ:NVCR) said today that Radiation Therapy Oncology Group Foundation won FDA investigational device exemption to conduct a Phase II pilot test of NovoCure’s Optune in conjunction with bevacizumab to treat bevacizumab-refractory recurrent glioblastoma. The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit […]
Novocure wins reimbursement from Humana for Optune brain cancer device
NovoCure (NSDQ:NVCR) said today it won reimbursement from Humana for treatments with its Optune device for patients with recurrent glioblastoma. The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields,” to inhibit cancer cell replication and cause cancer cell death. The new reimbursement win brings the […]